These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17013817)

  • 1. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
    Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
    Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
    Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
    Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
    Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
    Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
    Borthakur G; Lin E; Faderl S; Ferrajoli A; Wierda W; Giles F; Browning ML; Kantarjian H; Keating M; O'Brien S
    Cancer; 2007 Dec; 110(11):2478-83. PubMed ID: 17960607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
    Halaburda K; Nasiłowska-Adamska B; Grabarczyk P; Szczepiński A; Szpila T; Warzocha K; Mariańska B
    Ann Transplant; 2007; 12(2):37-40. PubMed ID: 18173065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
    Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
    Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
    Capria S; Gentile G; Capobianchi A; Cardarelli L; Gianfelici V; Trisolini SM; Foà R; Martino P; Meloni G
    J Med Virol; 2010 Jul; 82(7):1201-7. PubMed ID: 20513085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
    Alinari L; Geskin L; Grady T; Baiocchi RA; Bechtel MA; Porcu P
    Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
    Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
    J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
    Anoop P; Wotherspoon A; Matutes E
    Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
    [No Abstract]   [Full Text] [Related]  

  • 17. Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.
    Medd P; Littlewood S; Danby R; Malladi R; Clifford R; Wareham D; Jeffery K; Ferry B; Roberts D; Peniket A; Littlewood T
    Bone Marrow Transplant; 2011 Jul; 46(7):993-9. PubMed ID: 20956951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
    Song WK; Min YH; Kim YR; Lee SC
    Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.